Tylosin Market Analysis & Forecast: 2026-2033
The Tylosin Market size is anticipated to grow at a CAGR of 4.34% with USD 830 Mn in 2026 and is expected to reach USD 1,120 Mn in 2033. The primary drivers are largely defined by rising bacterial disease burden in livestock, wider use of veterinary antibiotics, and growing demand for poultry, swine, and cattle health management. Some of the other contributing factors include increasing respiratory infections, enteric diseases, liver abscess prevention in feedlot cattle, and greater veterinary supervision in commercial farms. FDA notes that tylosin phosphate is approved in beef cattle to reduce liver abscess incidence, while WOAH continues to emphasize prudent antimicrobial use in animals, supporting regulated demand in the Tylosin Market.
On the basis of drug type, the tylosin phosphate segment is projected to account for the largest Tylosin Market share of 48.2% in 2026. The segment’s growth is owing to its established feed-use role in beef cattle for reducing liver abscess incidence.
FDA states that tylosin phosphate, marketed as Tylan 40 or Tylan 100 Type A medicated article, is approved for beef cattle to reduce liver abscesses caused by Fusobacterium necrophorum and Arcanobacterium pyogenes.
FDA’s 2024 antimicrobial sales report also showed that domestic sales and distribution of medically important macrolides reached 333,653 kg for food-producing animals, supporting continued relevance of tylosin-class products in livestock treatment channels. Another supporting statistic is the approved tylosin dosage of 60–90 mg/head/day for beef cattle.
A key development is FDA-funded research evaluating targeted 30- and 60-day tylosin phosphate duration for feedlot steers, supporting more stewardship-aligned use.
To learn more about this report, Request Free Sample
On the basis of application, the livestock segment lead with a major 72.4% share in 2026. The segment’s growth is owing to the sustained demand for disease control and productivity management across cattle, swine, and poultry.
The growth of this segment is supported by high livestock processing volumes. According to the USDA, U.S. commercial red meat production reached 55.0 billion pounds in 2024, including 54.9 billion pounds from commercial plants.
The segment continued to reflect strong treatment demand in 2025, as the USDA reported 53.7 billion pounds of commercial red meat production during January–December 2025.
In October 2024, Phibro Animal Health completed the acquisition of Zoetis’ medicated feed additive and water-soluble product portfolio. The acquisition expanded Phibro’s livestock health portfolio across cattle, swine, and poultry, strengthening its medicated feed additive business.
Antimicrobial resistance pressure is transforming the U.S. tylosin market by pushing use toward stricter veterinary supervision and more targeted treatment in food-producing animals.
The FDA’s 2024 antimicrobial sales report showed that the sales of medically important antimicrobials for food-producing animals increased by 16% from 2023 to 2024, thereby indicating the continued demand for therapeutic livestock treatment. However, the total 2024 sales remained 27% below the 2015 peak, thereby reflecting the long-term effect of stewardship policies on antibiotic consumption.
The FDA-funded research has strengthened more specific tylosin phosphate duration-of-use guidance for reducing liver abscesses in beef cattle. This is encouraging label refinement, controlled administration, as well as stewardship-aligned prescribing in the U.S. livestock sector.
The tylosin market is moving toward stricter veterinary prescription control. The regulators are focusing on antimicrobial resistance and responsible use of livestock antibiotics.
In June 2023, the U.S. FDA completed GFI #263 implementation, moving remaining over-the-counter medically important animal antimicrobials like tylosin-related products to prescription status. This shift is improving veterinarian-led treatment decisions, minimizing casual farm-level antibiotic access, and promoting more controlled demand through the licensed distribution channels.
It is also encouraging livestock producers to use tylosin only under professional supervision, improving dosage discipline and treatment accountability. As a result, the market is moving toward regulated, stewardship-aligned demand rather than the unrestricted antibiotic consumption.
|
Current Event |
Description and its Impact |
|
U.S. FDA Prescription Status for Medically Important Animal Antibiotics
|
|
|
EU Antibiotic Stewardship and Farm Animal Medicine Controls |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 34.6% of the market share in 2026. The region’s growth is owing to the large cattle feedlot base and sustained beef production. The region is growing as tylosin remains important for liver abscess control in feedlot cattle, where herd size and intensive finishing systems create consistent demand for medicated feed solutions.
USDA reported that cattle and calves on feed for slaughter totaled 13.8 million head on January 2026, indicating a strong addressable base for veterinary antimicrobials. USDA’s 2025 Livestock Slaughter Summary also reported that U.S. beef production totaled 26.1 billion pounds in 2025, thereby supporting the continued cattle health management needs.
In July 2025, Huvepharma EOOD received approval for Tylovet (tylosin phosphate) with MGA, Experior, and Monovet for confined beef heifers. The combination supports weight gain, feed efficiency, coccidiosis control, ammonia emission reduction, and liver abscess reduction.
Asia Pacific is expected to witness strong growth in Tylosin Market over the forecast period. The region’s growth is owing to large livestock and poultry population, rising demand for animal protein, and increasing need for veterinary disease management.
India’s Department of Animal Husbandry reported 536.76 million livestock and 851.81 million poultry in 2024–25, creating a strong treatment base for veterinary antimicrobials such as tylosin. The region also has high antimicrobial use in food-producing animals, as WOAH reported 51,145 tonnes of antimicrobial agents intended for animal use in Asia and the Pacific in 2021.
The growth is further supported by China’s National Action Plan to Contain Antimicrobial Resistance, 2022–2025, which promotes rational antimicrobial use in animals. This regulatory shift is increasing prescription-led tylosin use and supporting steady market growth across livestock and poultry farms.
The U.S. Tylosin Market is expanding at a rapid pace because tylosin remains an FDA-approved medicated feed ingredient for livestock disease management.
In October 2024, the FDA approved a medicated-feed combination containing MGA, Experior, Rumensin, and Elanco’s Tylan for growing beef heifers fed in confinement. The FDA’s approval summary states that tylosin phosphate is used at 8–10 g/ton, delivering 60–90 mg per head per day, to reduce liver abscess incidence in beef cattle.
This approval supports market growth by maintaining tylosin’s role in regulated feed programs and strengthening demand from cattle producers, feed manufacturers, and veterinary-supervised livestock treatment channels.
The growth in China’s Tylosin Market is driven by the country’s large commercial swine base and continued regulatory availability of tylosin phosphate premix for livestock use.
In January 2026, China’s National Bureau of Statistics reported that 719.73 million pigs were slaughtered in 2025, showing a sizeable treatment base for veterinary antimicrobials used in herd-health management.
A direct market development came in February 2025, when China’s Ministry of Agriculture and Rural Affairs re-registered Elanco Clinton Laboratories’ Tylosin Phosphate Premix in 100g:8.8g and 100g:22g strengths, keeping the imported veterinary medicine certificate valid until February 2030.
Some of the major key players in Tylosin Market are Zoetis, Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, and Elanco Animal Health.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 830 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.34% | 2033 Value Projection: | USD 1,120 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Zoetis, Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, and Elanco Animal Health. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
